INS and type 2 diabetes mellitus: People with type 2 diabetes receiving sulphonylureas have reported hypoglycaemia in comparable proportions to those receiving insulin for less than 2 years, with 7% in both groups reporting severe hypoglycaemia and 39 and 51%, respectively, reporting mild hypoglycaemia [17].